Back

Efficacy and safety of semaglutide in patients with obesity-related heart failure: a meta-analysis of randomized clinical trials

3 April 2025 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Effectively addressing adiposity as a cardiovascular risk factor Obesity EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Radhika Gulhar

Riverside Community Hospital, Riverside (United States of America)

6 More presentations in this session

Presentation thumbnail
Exercise limitations in heart failure with preserved ejection fraction and obesity: is the issue the engine or chassis?
Doctor S. Foulkes (Fitzroy, AU)
Abstract Slides
Presentation thumbnail
Long-term effect of intensive lifestyle intervention among obese arab women: a cohort study
Associate Professor O. Kalter-Leibovici (Ramat Gan, IL)
Abstract Slides
Presentation thumbnail
My worst nightmare: obesity and hypertension
Ms K. Liu (Lausanne, CH)
Abstract Slides
Presentation thumbnail
Not a light matter: obesity diagnosis rates among obese hospitalized patients
Doctor I. Avivi (San Diego, US)
Abstract Slides
Presentation thumbnail
PreveCardio program: from research to practice, impact on obesity, overweight, Mediterranean diet adherence, and physical activity patterns in a European population
Doctor J. Flores Soler (Madrid, ES)
Abstract Slides

Access the full session

Session thumbnail
Effectively addressing adiposity as a cardiovascular risk factor

The Event

Event poster

ESC Preventive Cardiology 2025

3 April 2025 13:30 CET
You may be interested in
thumbnail
Congress Session
Obesity as a cardiovascular disease: integrated management
thumbnail
Webinar
Obesity management: implications for cardiovascular risk reduction
thumbnail
Congress Presentation
Impact of obesity on cardiovascular disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources